SCHEMBL24101206

SCHEMBL24101206

O=C(Nc1cc(F)cc(F)c1)c1nnsc1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 7/20 0.73
▸ ALDH1A1 P00352 6/20 0.73
▸ KMT2A Q03164 6/20 0.73
▸ MEN1 O00255 4/20 0.73
▸ S1PR4 O95977 3/20 0.73
▸ HSP90AA1 P07900 2/20 0.73
▸ HPGD P15428 2/20 0.73
▸ ALOX12 P18054 2/20 0.73
▸ S1PR1 P21453 2/20 0.73
▸ POLB P06746 1/20 0.73
▸ PKM P14618 1/20 0.73
▸ NPSR1 Q6W5P4 6/20 0.65
▸ NPC1 O15118 6/20 0.65
▸ LMNA P02545 6/20 0.65
▸ SMN1; SMN2 Q16637 5/20 0.65
▸ RAB9A P51151 4/20 0.65
▸ AGTR1 P30556 1/20 0.65
▸ GPR55 Q9Y2T6 1/20 0.65
▸ L3MBTL1 Q9Y468 1/20 0.65
▸ MAPT P10636 7/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24101112 0.96 ALDH1A1 (0.71) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL25994858 0.93 ALDH1A1 (0.67) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL24100990 0.91 ALDH1A1 (0.64) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL24100858 0.90 ALDH1A1 (0.76) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL25352892 0.90 HTT (0.72) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL13802907 0.90 ALDH1A1 (0.79) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL24100407 0.88 KMT2A (0.88) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL24100884 0.88 KMT2A (0.72) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL24100943 0.88 HTT (0.65) HTTALDH1A1KMT2AMEN1S1PR4
SCHEMBL24101317 0.87 KMT2A (0.71) HTTALDH1A1KMT2AMEN1S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233533-A1 COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION HEALTH RESEARCH, INC. (US) 2023-07-27 — — US disclosed
US-20230233533-A1 COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION HEALTH RESEARCH, INC. (US) 2023-07-27 — — US disclosed
WO-2021252068-A1 COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION HEALTH RESEARCH, INC. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233533-A1 COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION PRPF8, PRPF40A, PRPF19 HTT 3823/4885ALDH1A1 3731/4885KMT2A 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback